Osimertinib, a revolutionary treatment for treating lung tumor, has recently been approved by the FDA (FDA).The FDA's endorsement of osimertinib marks a important landmark in the battle with this deadly disease, offering new hope to countless patients globally.Osimertinib, a specific therapy, has demonstrated remarkable effectiveness in treating individuals affected by non-small cell lung tumor (NSCLC), who have mutations in the EGFR mutation.The process of osimertinib is crucial for both medical staff and patients to understand, as it assists in identifying the most appropriate candidates for this treatment.Early detection of EGFR…
